BIOKIN PHARMACEUTICAL(688506) 海通证券·2024-11-13 06:42Investment Rating - The investment rating for the company is "Outperform the Market" [1] Core Insights - The report highlights significant clinical advancements for the company's drug candidates, particularly BL-B01D1 and BL-M11D1, which are expected to be key catalysts for growth in 2025 [4][5] - The company is projected to achieve a substantial increase in revenue in 2024, with an estimated operating income of 6.213 billion yuan, representing a year-on-year growth of 1005.8% [6][11] - The report anticipates a return to profitability in 2024, with a forecasted net profit of 4.089 billion yuan and an earnings per share (EPS) of 10.20 yuan [6][11] Summary by Sections Clinical Development - Event 1: BMS has updated its clinical advancement plan for BL-B01D1, with expected results from Phase I trials in 2025, which are considered critical milestones [4] - Event 2: The company will present early clinical data for CD33 ADC BL-M11D1 at the 2024 ASH conference, showing promising treatment potential for r/r AML patients [5][8] Financial Forecast - The company is expected to report a net profit of 4.089 billion yuan in 2024, with a projected EPS of 10.20 yuan [6][11] - Revenue is forecasted to increase significantly in 2024, with a total operating income of 6.213 billion yuan [6][11] Market Potential - The report identifies a large unmet clinical need in the r/r AML market, with over 40,000 new cases annually in China and over 20,000 in the U.S. [7] - BL-M11D1 targets CD33, which is expressed in approximately 85-90% of AML patients, indicating a broad potential treatment scope [8]